Sign in

    Keonhee Kim

    Research Analyst at Morningstar, Inc.

    Keonhee Kim is an Equity Analyst specializing in healthcare at Morningstar, Inc., where he covers leading healthcare technology, distribution, and device companies such as Walgreens Boots Alliance, Veeva Systems, Kenvue, McKesson, and Cencora. Renowned for thorough sector research, Kim has contributed analysis featured by outlets like CNN, Schwab Network, and Crain’s Chicago, though specific success rates or performance metrics are not publicly available. He began his career at Bank of America as an intern, joined Morningstar in 2020 as part of the commodities and energy team, then advanced to the industrials team before assuming his current role in healthcare equity research. Kim holds a bachelor's degree in applied mathematics with a concentration in economics from the University of California, Berkeley.

    Keonhee Kim's questions to TEVA PHARMACEUTICAL INDUSTRIES (TEVA) leadership

    Keonhee Kim's questions to TEVA PHARMACEUTICAL INDUSTRIES (TEVA) leadership • Q2 2025

    Question

    Keonhee Kim from Morningstar, Inc. asked about the commercial progress of the Selarsity (ustekinumab biosimilar) rollout and whether its market dynamics are similar to the slow uptake seen with Humira biosimilars.

    Answer

    President and CEO Richard Francis responded that every biosimilar launch is unique and the team is executing well. He emphasized that Teva's confidence is rooted in its broad portfolio strategy, which includes launching eight biosimilars by 2027, and does not depend on any single product becoming a 'superstar' to achieve its revenue goals.

    Ask Fintool Equity Research AI